Editorial Volume 9, Issue 10 pp 2010—2011
CA125 effects on humoral immunosuppression
Figure 1. Model depicting farletuzumab ADCC by NK cells on FRA-expressing tumor cells (top) and ADCC suppression by direct binding of CA125 to antibody (bottom).
Figure 1. Model depicting farletuzumab ADCC by NK cells on FRA-expressing tumor cells (top) and ADCC suppression by direct binding of CA125 to antibody (bottom).